23.13
Elanco Animal Health Inc stock is traded at $23.13, with a volume of 3.44M.
It is down -1.41% in the last 24 hours and down -2.28% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$23.46
Open:
$23.65
24h Volume:
3.44M
Relative Volume:
0.68
Market Cap:
$11.55B
Revenue:
$4.72B
Net Income/Loss:
$-232.00M
P/E Ratio:
-49.60
EPS:
-0.4663
Net Cash Flow:
$284.00M
1W Performance:
+0.22%
1M Performance:
-2.28%
6M Performance:
+17.05%
1Y Performance:
+165.56%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Inc
|
23.13 | 11.72B | 4.72B | -232.00M | 284.00M | -0.4663 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
117.86 | 50.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
9.84 | 44.61B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.82 | 36.05B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
571.73 | 25.19B | 3.18B | 1.33B | 1.04B | 27.90 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Where is Elanco Animal Health Incorporated (ELAN) headed according to the Street? - MSN
Q3 2025 Elanco Animal Health Inc Earnings Call Transcript - GuruFocus
Elanco Animal Health Inc Investor Day Transcript - GuruFocus
Dimensional Fund Advisors (NYSE: ELAN) reports 24.5M shares beneficially owned - Stock Titan
Elanco Animal Health Inc (ELAN) Shares Gap Down to $22.82 on Apr 9 - GuruFocus
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* - Barchart.com
Aug Sectors: Can Elanco Animal Health Incorporated expand its profit marginsLayoff News & Weekly Market Pulse Alerts - baoquankhu1.vn
Form DEF 14A Elanco Animal Health For: Dec 31 - StreetInsider
[DEF 14A] Elanco Animal Health Inc Definitive Proxy Statement - Stock Titan
BofA Securities Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Elanco (ELAN) executive awarded new deferred stock units under deferral plan - Stock Titan
Elanco (NYSE: ELAN) CEO awarded new deferred stock units as compensation - Stock Titan
Elanco (ELAN) CFO awarded new deferred stock units in Form 4 filing - Stock Titan
Elanco (ELAN) officer granted 40,985 shares, with 20,288 withheld for taxes - Stock Titan
Stifel reiterates buy on Elanco stock, keeps $32 price target - Investing.com
ELAN Technical Analysis | Trend, Signals & Chart Patterns | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
IVF In Animals Market Generated Opportunities, Future Scope - openPR.com
Veterinary Medication Market Set for Dynamic Boom as Key Players - openPR.com
Harbor Capital Advisors Inc. Sells 49,302 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
ELAN Technical Analysis & Stock Price Forecast - intellectia.ai
ELAN PE Ratio & Valuation, Is ELAN Overvalued - Intellectia AI
Maryland judge dismisses securities class action against Elanco over Zenrelia disclosures - DVM360
Elanco (ELAN) director defers fees into 600 Deferred Stock Units - Stock Titan
ELAN Stock Price, Quote & Chart | ELANCO ANIMAL HEALTH INC (NYSE:ELAN) - ChartMill
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assessing Elanco Animal Health’s Valuation After Recent Share Price Swings And Product Launch Momentum - Yahoo Finance
Chewy reaches settlement in Elanco flea and tick antitrust litigation - DVM360
Elanco supports incubaFORUM ASIA 2026 as Premium-Platinum Sponsor - avinews.com
Decoquinate Market Is Going to Boom Rapidly With Top Key Players - openPR.com
Companion Animal Health Market Forecast 2026-2033 Featuring Strategic Analysis of Agrolabo, Boehringer Ingelheim, Ceva, Elanco, IDEXX Labs and More - Yahoo Finance
Elanco Animal Health Inc (ELAN) Shares Gap Down to $23.21 on Mar 27 - GuruFocus
Elanco Beats Investor Suit Over Dog Drug's Reg Challenges - Law360
Elanco Animal Health Drops More Than 5% – What’s Behind the Abrupt Decline? - Bitget
Vanguard reports 0 shares of Elanco after realignment (NYSE: ELAN) - Stock Titan
Elanco Gets Investors’ Dog Itch Drug Development Suit Dismissed - news.bloomberglaw.com
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost - MSN
Syngulon announces licensing agreement with Elanco Animal Health - PRWeb
Elanco (ELAN) CEO receives deferred stock units in compensation grant - Stock Titan
Elanco (NYSE: ELAN) executive receives new deferred stock unit grant - Stock Titan
Elanco (ELAN) CFO receives 8.216 deferred stock units as compensation award - Stock Titan
Elanco Animal (ELAN) climbs 7.6% on upbeat outlook, sets sights on AI - MSN
ELAN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pricier vet care: Fewer visits but still many $11,000 surgeries - Fortune
JPMorgan Chase & Co. Has $38.64 Million Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
New Mexico Educational Retirement Board Invests $2 Million in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Inc (ELAN) Shares Down 3.01% on Mar 20 - GuruFocus
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board - The Manila Times
Former Elanco director joins ImmuCell board in calf-health push - Stock Titan
Animal Health Market size to reach $199.1 Billion by 2035 | Key - openPR.com
Elanco Animal Health (ELAN) Surges 7.6%: Is This an Indication of Further Gains? - Yahoo Finance
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):